Evidence map›Paper›PMID 40667713›Full record

ArticleDiabetes, obesity & metabolism2025

Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.

Hannah Wallace, James Wick, Brendon L Neuen, Luke Buizen, Sunil V Badve, John Chalmers, Juliana de Oliveira Costa, Michael O Falster, Jeffrey T Ha, Meg J Jardine and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Hannah WallaceThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-2728-4299
James WickDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Brendon L NeuenThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-9276-8380
Luke BuizenThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
Sunil V BadveThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
John ChalmersThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
Juliana de Oliveira CostaSchool of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.
Michael O FalsterSchool of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-6444-7272
Jeffrey T HaThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
Meg J JardineSchool of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.
Daniel Bekele KetemaThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
Jialing LinSchool of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-0643-9191
Craig NelsonWestern Health, Melbourne, Victoria, Australia.
Sallie-Anne PearsonSchool of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.
David PeirisThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
Anthony RodgersThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
Takaya SasakiThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-9525-2638
Mark WoodwardThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-9800-5296
Martin GallagherThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
Sradha S KotwalThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-3294-4087
Paul RonksleyDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Min JunThe George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-1460-7535

Funding

Boehringer IngelheimEli Lilly AustraliaUniversity of New South Wales
6 · The paper itself

Abstract

aimsSodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have cardio-kidney-metabolic benefit. This study aimed to understand the prevalence of prescription of SGLT2 inhibitors and GLP1-RA among patients with T2DM with and without chronic kidney disease (CKD) in Australian primary care. MATERIALS AND

methodsWe conducted a retrospective, cohort study of adults with T2DM who attended primary care practices participating in MedicineInsight. The outcome of interest was the percentage of patients with CKD who received ≥1 prescription for an SGLT2 inhibitor or a GLP1-RA (assessed separately) compared to those without CKD during 2020-2021. We also assessed prescriptions in a sub-population of CKD patients who met trial inclusion criteria: SGLT2 inhibitor (estimated glomerular filtration rate [eGFR] ≥20 mL/min/1.73m

resultsOf 114 499 adults with T2DM, 36 840 (32.1%) also had CKD. SGLT2 inhibitors were prescribed in 13.6% of patients without CKD, 14.4% of patients with CKD and 17.8% of patients meeting the trial target population definition. Across these groups, GLP1-RA were prescribed in 8.8%, 10.1% and 11.3% of patients, respectively. More advanced CKD stage and severely increased albuminuria were associated with a lower likelihood of SGLT2 inhibitor or GLP1-RA being prescribed.

conclusionWe observed low rates of SGLT2 inhibitor and GLP1-RA prescriptions in patients with T2DM irrespective of CKD status. Strategies are needed to improve prescription rates, with a particular focus on patients with high kidney and cardiovascular risk.

Indexed as

Diabetes Mellitus, Type 2Drug PrescriptionsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAgedAustraliaDiabetic NephropathiesFemaleGlomerular Filtration RateHumansMaleMiddle AgedPractice Patterns, Physicians'PrevalenceGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitorschronic kidney diseaseglucagon‐like peptide‐1 receptor agonistsprimary caresodium‐glucose co‐transporter 2 inhibitorstype 2 diabetes mellitus

Identifiers

PMID40667713
PMCPMC12409226

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.